Metrogyl (Metronidazole)

Metronidazole is reduced inside anaerobic organisms to nitro radical anions that damage DNA and inhibit nucleic acid synthesis, leading to cell death. This selective activation makes it effective against anaerobes and certain protozoa while sparing aerobic cells.

The dosage regimen is determined by the prescribing clinician based on infection type, severity, patient weight, renal and hepatic function, and local guidelines. No standard dose is provided here; the prescriber sets the appropriate regimen.

Safety in pregnancy and lactation has not been fully established. Clinicians weigh potential benefits against risks, generally avoiding use unless clearly needed. Breastfeeding mothers should consult a healthcare professional before using Metrogyl.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Metrogyl (metronidazole) is a nitroimidazole active specifically against anaerobic bacteria and certain protozoa, whereas many broad‑spectrum antibiotics (e.g., penicillins, cephalosporins) target aerobic organisms. Its unique mechanism makes it the drug of choice for infections where anaerobes predominate.

Store at ambient temperature, preferably below 25 °C, in the original packaging. Protect from moisture, direct sunlight and extreme temperatures to maintain stability. Do not freeze the solution.

Metrogyl is supplied as a sterile intravenous solution and is administered by a qualified healthcare professional through an IV infusion. The infusion rate and duration are set by the prescriber according to the clinical situation.

Serious adverse reactions include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, seizures, hepatotoxicity, neutropenia, and peripheral neuropathy. Patients should be monitored for these rare but potentially life‑threatening events.

Individuals with a known hypersensitivity to metronidazole or other nitroimidazoles should avoid the drug. Caution is also advised for patients with severe hepatic impairment, and it is contraindicated in those with a history of severe disulfiram‑like reactions to alcohol.